Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.
You may also be interested in...
Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma
Merck And J&J Settle Remicade Dispute By Redrawing The Map
Johnson & Johnson Inc. and Merck & Co. Inc. settled their two-year dispute over Remicade (infliximab) and its successor Simponi (golimumab) April 15, avoiding an arbitrator's decision by striking a revised agreement under which each will retain some territorial rights to the drugs
Korea FDA Unveils Initial Biosimilar Guidance; Final Guidelines To Be Released In July
SEOUL - South Korea's FDA is putting the final touches on its EU-modeled initial guidelines for approval and registration of biosimilar products, and anticipates releasing a final version by the end of July